Multilocus genetic profiling to empower drug trials and predict brain atrophy()

Designers of clinical trials for Alzheimer's disease (AD) and mild cognitive impairment (MCI) are actively considering structural and functional neuroimaging, cerebrospinal fluid and genetic biomarkers to reduce the sample sizes needed to detect therapeutic effects. Genetic pre-selection, howev...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kohannim, Omid, Hua, Xue, Rajagopalan, Priya, Hibar, Derrek P., Jahanshad, Neda, Grill, Joshua D., Apostolova, Liana G., Toga, Arthur W., Jack, Clifford R., Weiner, Michael W., Thompson, Paul M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3777716/
https://ncbi.nlm.nih.gov/pubmed/24179834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nicl.2013.05.007
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller